Home / Pharmaceutical / Global Pharmacovigilance Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 To 2025

Global Pharmacovigilance Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 To 2025

Published: Nov 2017 | Published By: Acute Market Research

Pharmacovigilance Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017 - 2025, the pharmacovigilance market was valued at USD 2,841.6 Mn in 2017, and is expected to reach USD 5,570.9 Mn by 2025, expanding at a CAGR of 15.8% from 2017 to 2025.

Market Insights

Increasing demands on pharmaceutical manufacturers and other intermediaries regarding early identification of drug adversities, growing concerns over drug safety and growing need for prompt compliance to regulatory guidelines have led to emergence of pharmacovigilance services. Moreover, withdrawals of several high profile drugs in the past have urged pharmaceutical manufacturers to closely observe GPvP practices to preserve their stronghold in the market.

Among the phases of drug development namely, preclinical studies, phase I, phase II, phase III, phase IV or post marketing surveillance, phase IV segment is the largest revenue generating segment in the pharmacovigilance market. Standing at above 55% market share in 2015, as this stage is highly instrumental in assessing drug safety in the widest range of patients and registers the highest number of events. Phase IV assessment is also highly instrumental in product life cycle management of high profile drugs. In addition, phase III stage pharmacovigilance enables convenient and robust commercialization of novel drugs thus ensuring strong future foothold in the market.

Spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring, and EHR mining are the major methods of pharmacovigilance reporting. Our analysis estimates spontaneous reporting to be the largest segment in 2015 and is expected to maintain its dominance during the through the forecast period. Efficient identification of adverse effects that were previously unknown and less expensive processing are the major contributors to the market growth of this segment.

Pharmacovigilance is conducted either in-house or through contract outsourcing. Between the two options, the later method is the most widely adopted by both large and mid-sized pharmaceutical companies. The trend of adopting in-house pharmaceutical is thus expected to be low in the future due to growing preference of pharmaceutical manufacturers towards cost containment of operations and their growing focus on developing core competencies.

Geographically, North America and Europe take over half the pharmacovigilance market. Asia-Pacific, on the other hand, is anticipated to be the fastest growing regional market for pharmacovigilance due to growing awareness in the emerging economies, and government initiatives regarding drug safety. This market is observed to be highly fragmented with several BPOs and CROs currently operational in the international markets. PAREXEL International, Covance, Quintiles, Accenture, Cognizant Technology Solutions are some of the notable names in this market.

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Pharmacovigilance Market Share, by Drug Development Phase, 2015 (Value %)
2.2 Pharmacovigilance Market, by Methods, 2015-2025 (USD Mn)
2.3 Pharmacovigilance Market, by Services, 2015-2025 (USD Mn)
2.4 Pharmacovigilance Market Share, by Geography, 2015 (Value %)

Chapter 3 Pharmacovigilance Market: Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.2 Drivers
3.3 Challenges
3.4 Future Prospects
3.5 Attractive Investment Proposition
3.1 Competitive Analysis: Fractal Map Investigation, by Key Market Players

Chapter 4 Global Pharmacovigilance Market Analysis, by Drug Development Phase
4.1 Preface
4.2 Preclinical Studies
4.3 Phase I
4.4 Phase II
4.5 Phase III
4.6 Phase IV or Post Marketing Surveillance

Chapter 5 Global Pharmacovigilance Market Analysis, by Reporting Methods
5.1 Preface
5.2 Spontaneous Reporting
5.3 Intensified ADR Reporting
5.4 Targeted Spontaneous Reporting
5.5 Cohort Event Monitoring
5.6 EHR Mining

Chapter 6 Global Pharmacovigilance Market Analysis, by Services
6.1 Preface
6.2 Chemotherapy
6.3 Contract Outsourcing

Chapter 7 Global Pharmacovigilance Market, by Geography
7.1 Preface
7.2 North America
7.3 Europe
7.4 Asia-Pacific
7.5 Middle East and Africa (MEA)
7.6 Latin America

Chapter 8 Company Profiles
8.1 Accenture Plc.
8.1.1 Business Description
8.1.2 Financial Health and Budget Allocation
8.1.3 Product Positions/Portfolio
8.1.4 News Coverage
8.2 Bristol-Myers Squibb
8.2.1 Business Description
8.2.2 Financial Health and Budget Allocation
8.2.3 Product Positions/Portfolio
8.2.4 News Coverage
8.3 Clinquest Group B.V.
8.3.1 Business Description
8.3.2 Financial Health and Budget Allocation
8.3.3 Product Positions/Portfolio
8.3.4 News Coverage
8.4 Cognizant Technology Solutions
8.4.1 Business Description
8.4.2 Financial Health and Budget Allocation
8.4.3 Product Positions/Portfolio
8.4.4 News Coverage
8.5 Covance, Inc.
8.5.1 Business Description
8.5.2 Financial Health and Budget Allocation
8.5.3 Product Positions/Portfolio
8.5.4 News Coverage
8.6 F. Hoffmann-La Roche Ltd.
8.6.1 Business Description
8.6.2 Financial Health and Budget Allocation
8.6.3 Product Positions/Portfolio
8.6.4 News Coverage
8.7 GSK
8.7.1 Business Description
8.7.2 Financial Health and Budget Allocation
8.7.3 Product Positions/Portfolio
8.7.4 News Coverage
8.8 ICON plc
8.8.1 Business Description
8.8.2 Financial Health and Budget Allocation
8.8.3 Product Positions/Portfolio
8.8.4 News Coverage
8.9 iGATE Corporation
8.9.1 Business Description
8.9.2 Financial Health and Budget Allocation
8.9.3 Product Positions/Portfolio
8.9.4 News Coverage
8.10 iMEDGlobal Corporation
8.10.1 Business Description
8.10.2 Financial Health and Budget Allocation
8.10.3 Product Positions/Portfolio
8.10.4 News Coverage
8.11 inVentiv Health, Inc.
8.11.1 Business Description
8.11.2 Financial Health and Budget Allocation
8.11.3 Product Positions/Portfolio
8.11.4 News Coverage
8.12 PAREXEL International Corporation
8.12.1 Business Description
8.12.2 Financial Health and Budget Allocation
8.12.3 Product Positions/Portfolio
8.12.4 News Coverage
8.13 PRA Health Sciences, Inc.
8.13.1 Business Description
8.13.2 Financial Health and Budget Allocation
8.13.3 Product Positions/Portfolio
8.13.4 News Coverage
8.14 Quintiles Transnational Holdings, Inc.
8.14.1 Business Description
8.14.2 Financial Health and Budget Allocation
8.14.3 Product Positions/Portfolio
8.14.4 News Coverage
8.15 Synowledge LLC
8.15.1 Business Description
8.15.2 Financial Health and Budget Allocation
8.15.3 Product Positions/Portfolio
8.15.4 News Coverage
8.16 Wipro Limited
8.16.1 Business Description
8.16.2 Financial Health and Budget Allocation
8.16.3 Product Positions/Portfolio
8.16.4 News Coverage
8.17 Others

TABLE 1 Global Pharmacovigilance Market, by Drug Development Phase, 2015 – 2025 (USD Mn)
TABLE 2 Global Pharmacovigilance Market, by Reporting Methods, 2015 – 2025 (USD Mn)
TABLE 3 Global Pharmacovigilance Market, by Services, 2015 – 2025 (USD Mn)
TABLE 4 Global Pharmacovigilance Market, by Geography, 2015 – 2025 (USD Mn)
TABLE 5 North Pharmacovigilance Market, by Country, 2015 – 2025 (USD Mn)
TABLE 6 Europe Pharmacovigilance Market, by Country, 2015 – 2025 (USD Mn)
TABLE 7 Asia-Pacific Pharmacovigilance Market, by Country, 2015 – 2025 (USD Mn)

FIG. 1 Pharmacovigilance: Market Segmentation
FIG. 2 Pharmacovigilance Market Share, by Drug Development Phase, 2015 (Value %)
FIG. 3 Pharmacovigilance Market, by Methods, 2015 - 2025 (USD Mn)
FIG. 4 Pharmacovigilance Market, by Services, 2015 - 2025 (USD Mn)
FIG. 5 Pharmacovigilance Market Share, by Geography, 2015 (Value %)
FIG. 6 Attractive Investment Proposition, Pharmacovigilance Market, 2015
FIG. 7 Competitive Analysis: Fractal Map Investigation, by Key Market Players
FIG. 8 Global Preclinical Studies Market, 2015 – 2025 (USD Mn)
FIG. 9 Global Phase I Pharmacovigilance Market, 2015 – 2025 (USD Mn)
FIG. 10 Global Phase I Pharmacovigilance Market, 2015 – 2025 (USD Mn)
FIG. 11 Global Phase III Pharmacovigilance Market, 2015 – 2025 (USD Mn)
FIG. 12 Global Phase IV or Post Marketing Surveillance Pharmacovigilance Market, 2015 – 2025 (USD Mn)
FIG. 13 Global Spontaneous Reporting Market, 2015 – 2025 (USD Mn)
FIG. 14 Global Intensified ADR Reporting Market, 2015 – 2025 (USD Mn)
FIG. 15 Global Targeted Spontaneous Reporting Market, 2015 – 2025 (USD Mn)
FIG. 16 Global Cohort Event Monitoring Market, 2015 – 2025 (USD Mn)
FIG. 17 Global EHR Mining Market, 2015 – 2025 (USD Mn)
FIG. 18 Global In-House Pharmacovigilance Market, 2015 – 2025 (USD Mn)
FIG. 19 Global Contract Outsourcing Pharmacovigilance Market, 2015 – 2025 (USD Mn)
FIG. 20 U.S. Pharmacovigilance Market, 2015 - 2025 (USD Mn)
FIG. 21 Canada Pharmacovigilance Market, 2015 - 2025 (USD Mn)
FIG. 22 U.K. Pharmacovigilance Market, 2015 - 2025 (USD Mn)
FIG. 23 Germany Pharmacovigilance Market, 2015 - 2025 (USD Mn)
FIG. 24 Rest of Europe Pharmacovigilance Market, 2015 - 2025 (USD Mn)
FIG. 25 Japan Pharmacovigilance Market, 2015 - 2025 (USD Mn)
FIG. 26 China Pharmacovigilance Market, 2015 - 2025 (USD Mn)
FIG. 27 Rest of Asia-Pacific Pharmacovigilance Market, 2015 - 2025 (USD Mn)
FIG. 28 Middle East and Africa Pharmacovigilance Market, 2015 - 2025 (USD Mn)
FIG. 29 Latin America Pharmacovigilance Market, 2015 - 2025 (USD Mn)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +